Ascletis Pharma Inc.
1672
Rank in Stocks
#10362
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Share Price
$0.75348549
Market Cap
$790.90M
Change (1 day)
0.68%
Change (1 year)
-38.24%
Country
CN
Trade Ascletis Pharma Inc. (1672)
Category
Healthcare
Stock split history for Ascletis Pharma Inc. (1672)
Ascletis Pharma Inc. stock (symbol: 1672) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One 1672 share bought prior to Oct 20, 2026 would equal to 0 1672 shares today.
The most recent stock split occurred on Oct 20, 2026.
One 1672 share bought prior to Oct 20, 2026 would equal to 0 1672 shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
